Watch stocks you care about
Your own personalized stock watchlist!
It's a 100% FREE Motley Fool service...
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of Given Imaging (UNKNOWN: GIVN.DL ) , a diagnostics company that develops devices allowing for the visualization and detection of gastrointestinal tract disorders (e.g., the camera pill), skyrocketed by as much as 26% after Covidien (NYSE: COV ) agreed to purchase the company.
So what: Under the terms of the deal, Covidien will pay $30 in cash per share -- approximately $860 million -- to Given Imaging shareholders upon closing of the deal, which is expected to occur prior to March 31. The deal will expand Covidien's existing presence in the gastrointestinal device market and is expected to be earnings neutral to the company next year and earnings accretive thereafter. Both company boards have approved the deal.
Now what: The move certainly makes sense from the perspective of Covidien as it gives the company a broader array of GI devices and eliminates a potential competitor. At $30 per share, Covidien is not purchasing Given Imaging at a bargain (37 times forward earnings), but Covidien shareholders should trumpet this deal as it could be a driver of long-term growth for a company that's been middling along with a low-to-mid single-digit-growth rate.
Will this be the next explosive investment opportunity?
Opportunities to get wealthy from a single investment don't come around often, but they do exist, and our chief technology officer believes he's found one. In this free report, Jeremy Phillips shares the single company that he believes could transform not only your portfolio, but your entire life. To learn the identity of this stock for free and see why Jeremy is putting more than $100,000 of his own money into it, all you have to do is click here now.